Unitat de Senyalització Neuronal, Department Ciències Mèdiques Bàsiques, Universitat de Lleida-IRBLLEIDA, Lleida 25198, Spain.
Cell Death Dis. 2013 Jun 20;4(6):e686. doi: 10.1038/cddis.2013.209.
Spinal muscular atrophy (SMA) is a genetic disorder characterized by degeneration of spinal cord motoneurons (MNs), resulting in muscular atrophy and weakness. SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene and decreased SMN protein. SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoproteins and pre-mRNA splicing requirements. SMN reduction causes neurite degeneration and cell death without classical apoptotic features, but the direct events leading to SMN degeneration in SMA are still unknown. Autophagy is a conserved lysosomal protein degradation pathway whose precise roles in neurodegenerative diseases remain largely unknown. In particular, it is unclear whether autophagosome accumulation is protective or destructive, but the accumulation of autophagosomes in the neuritic beadings observed in several neurite degeneration models suggests a close relationship between the autophagic process and neurite collapse. In the present work, we describe an increase in the levels of the autophagy markers including autophagosomes, Beclin1 and light chain (LC)3-II proteins in cultured mouse spinal cord MNs from two SMA cellular models, suggesting an upregulation of the autophagy process in Smn (murine survival motor neuron protein)-reduced MNs. Overexpression of Bcl-xL counteracts LC3-II increase, contributing to the hypothesis that the protective role of Bcl-xL observed in some SMA models may be mediated by its role in autophagy inhibition. Our in vitro experimental data indicate an upregulation in the autophagy process and autophagosome accumulation in the pathogenesis of SMA, thus providing a valuable clue in understanding the mechanisms of axonal degeneration and a possible therapeutic target in the treatment of SMA.
脊髓性肌萎缩症(SMA)是一种遗传性疾病,其特征是脊髓运动神经元(MN)退化,导致肌肉萎缩和无力。SMA 是由生存运动神经元 1(SMN1)基因的突变和 SMN 蛋白的减少引起的。SMN 广泛表达,在小核核糖核蛋白的组装和前体 mRNA 剪接要求中具有一般作用。SMN 的减少导致轴突退化和细胞死亡,没有经典的凋亡特征,但导致 SMA 中 SMN 退化的直接事件仍不清楚。自噬是一种保守的溶酶体蛋白降解途径,其在神经退行性疾病中的确切作用仍知之甚少。特别是,自噬体的积累是保护性的还是破坏性的尚不清楚,但在几种轴突退化模型中观察到的神经丝珠状结构中的自噬体积累表明自噬过程与轴突崩溃之间存在密切关系。在本工作中,我们描述了两种 SMA 细胞模型中培养的小鼠脊髓 MN 中自噬标记物(包括自噬体、Beclin1 和轻链(LC)3-II 蛋白)水平的增加,表明 Smn(鼠生存运动神经元蛋白)减少的 MN 中自噬过程的上调。Bcl-xL 的过表达可拮抗 LC3-II 的增加,这有助于假设 Bcl-xL 在一些 SMA 模型中观察到的保护作用可能是通过其在自噬抑制中的作用介导的。我们的体外实验数据表明,自噬过程的上调和自噬体在 SMA 发病机制中的积累,为理解轴突退化的机制提供了有价值的线索,并为 SMA 的治疗提供了可能的治疗靶点。